To the Editor: In their recent article, Chen and colleagues argued for an increase in the number of Australians being treated with lipid-lowering drugs.1 It would appear pertinent to question the economic and therapeutic value of such an increase.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- Nu-Life Cardiac Programmes, Noosaville, QLD.
Correspondence: neaverson@neocardia.com
- 1. Chen L, Rogers SL, Colagiuri S, et al. How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999–2000. Med J Aust 2008; 189: 319-322. <eMJA full text> <MJA full text>
- 2. Senes S, Penm E. Medicines for cardiovascular health: are they used appropriately? Canberra: Australian Institute of Health and Welfare, 2007. (AIHW Cat. No. CVD 36.)
- 3. Lloyd-Jones DM, O’Donnell CJ, D’Agostino RB, et al. Applicability of cholesterol-lowering primary prevention trials to a general population: the Framingham Heart Study. Arch Intern Med 2001; 161: 949-954.
- 4. House of Representatives. Standing Committee on Health and Ageing. The Blame Game: report on the inquiry into health funding. Canberra: Parliament of the Commonwealth of Australia, November 2006: section 3.124.
- 5. Neaverson MA, Abell B, Bermingham M. Effect of exercise on emerging risk factors for cardiovascular disease [abstract]. Heart Lung Circ 2006; 15 Suppl 1: S166.
- 6. Australian Institute of Health and Welfare. Indicators for chronic diseases and their determinants 2008. Canberra: AIHW, 2008. (AIHW Cat. No. PHE 75.)
Online responses are no longer available. Please refer to our instructions for authors page for more information.